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Abstract: Recent developments in understanding the immunopathogenesis of rheumatoid 
arthritis (RA), combined with progress in biopharmaceutical development, have facilitated 
the introduction of novel immune modulating therapies for this progressive debilitating 
disorder. Efﬁ  cacy achieved with certain agents, particularly the TNF inhibitors, has spurred 
the development of additional biologic agents targeting other components of the dysregu-
lated immune response relevant to the etiology and sustenance of immune driven systemic 
inﬂ  ammation characteristic of RA. Among these other potential targets is IL-6, a cytokine with 
effects on numerous cell types, including those involved in the pathogenesis of RA. Based on 
its activities, IL-6 appeared to be a viable target for autoimmune disease. Inhibitors of IL-6 
were successful in animal models of autoimmune disease paving the way for subsequent studies 
in humans. The greatest experience to date has been with tocilizumab, a humanized monoclo-
nal antibody speciﬁ  c for the IL-6 receptor (IL-6R). Beginning with open label studies, and 
progressing through larger and more rigorous controlled trials, tocilizumab has been shown to 
have signiﬁ  cant efﬁ  cacy in patients with RA. Additional studies analyzing its effects in varied 
populations of RA patients, as well as greater detail concerning its longer-term tolerability 
and safety, will help deﬁ  ne the ultimate role of tocilizumab and other future inhibitors of IL-6 
activity as potential therapies for RA.
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Introduction to targeted treatments in rheumatoid 
arthritis: TNF and IL-6
Rheumatoid arthritis (RA) is a chronic, inﬂ  ammatory disease characterized by 
progressive, symmetric joint inﬂ  ammation and subsequent destruction. Left untreated, 
RA is associated with significant patient morbidity and accelerated mortality. 
Treatment with traditional disease modifying anti-rheumatic drugs (DMARDs) such 
as methotrexate (MTX) can be efﬁ  cacious for a number of RA patients. However, 
appreciation of the severity of the disease has led to elevation in the goals of treatment of 
RA. The desire for more complete control of disease, coincident with advances in under-
standing the underlying immunopathogenesis of RA, and progress in biopharmaceutical 
development, has spawned the introduction of novel biologic agents. Perhaps the 
greatest success has come with targeting those inﬂ  ammatory cytokines that exhibit 
key roles in the activation and continuation of the destructive process occurring in 
the rheumatoid synovium. To date, the most notable clinical success in the treatment 
of RA has been achieved through inhibition of tumor necrosis factor alpha (TNFα). 
Patients receiving anti-TNF agents have not only exhibited signiﬁ  cant improvement in 
arthritis signs and symptoms, but also better quality of life, less functional disability, 
and abrogation of joint damage (Gartlehner et al 2006). Despite these beneﬁ  ts, as with 
DMARDs not all patients respond or maintain efﬁ  cacy to desired standards. Therefore, 
new therapies for RA are needed.Therapeutics and Clinical Risk Management 2008:4(4) 768
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Interleukin-6 (IL-6) is a pleiotropic cytokine that is abundant 
in both the synovium and serum of RA patients. Locally in the 
joint, the major source of IL-6 may be synovial ﬁ  broblasts, with 
additional amounts released by activated macrophages and 
lymphocytes (Yoshizaki et al 1998). Originally identiﬁ  ed as a 
B-cell differentiation factor, IL-6 is now known to regulate a 
diverse array of activities may underlie both systemic as well as 
local symptoms of RA. For example, IL-6 initiates the acute-phase 
response inducing the hepatic synthesis of acute phase proteins 
including C-reactive protein (CRP), serum amyloid, haptoglobin, 
and ﬁ  brinogen among others (Cronstein 2007). IL-6 can also 
activate vascular endothelial cells, upregulating expression of 
certain chemokines and adhesion molecules, and facilitating 
leukocyte recruitment directly to sites of inﬂ  ammation (Lipsky 
2006). Excess production of IL-6 also contributes to the anemia 
of chronic disease common in active RA by increasing hepcidin 
production, and induces thrombocytosis through increased mega-
karyocyte differentiation (Ishibashi et al 1993; Andrews 2004. 
Its ability to induce B-cell differentiation may lead to hypergam-
maglobulinemia as well as the production of autoantibodies such 
as rheumatoid factor (RF) and autoantibodies to citrullinated 
peptides (Yoshizaki et al 1998). Additionally, IL-6 may prompt 
synovial ﬁ  broblast differentiation and osteoclast activation, con-
tributing to pannus formation and cartilage and bone destruction 
(Kudo et al 2003; Park and Pillinger 2007).
Dysregulation of IL-6 may provide an explanation for 
some of the common clinical manifestations associated 
with active RA, including fever, weight loss, fatigue, and 
poor appetite (Yoshizaki et al 1998). Signiﬁ  cant correlations 
between elevated levels of IL-6 and disease activity param-
eters including duration of morning stiffness and the Ritchie 
articular index have also been reported (Madhok et al 1993a). 
Furthermore, treatment of RA patients with methotrexate or 
gold therapy results in decreased levels of IL-6 in patients 
with concomitant improvement in additional measures of 
disease activity (Madhok et al 1993b; Straub et al 1997).
Given its many possible contributions to the pathogenesis 
of rheumatoid inflammation, IL-6 would appear to be 
an attractive therapeutic target in RA. Tocilizumab, a 
monoclonal antibody (mAb) speciﬁ  c for the IL-6 receptor 
(IL-6R) is the ﬁ  rst biologic agent targeting IL-6 that has 
progressed to late phase clinical trials.
Tocilizumab: pharmacology, 
mechanism of action, 
and pharmacokinetics
IL-6 mediates cell signaling by binding its cognate receptor 
(IL-6R; CD126). However, in order to transduce a signal, 
the combination of IL-6/IL-6R must also bind a ubiquitous 
transmembrane protein, glycoprotein (gp) 130 (CD130). The 
binding of IL-6R complexed with IL-6 results in homodi-
merization of gp130 and signal transduction through Janus-
activated kinase (JAK)/signal transducers and activators of 
transcription (STAT) pathways (Heinrich et al 2003). IL-6R 
is expressed on several cell types. However, IL-6 may also 
bind IL-6R in its soluble form. This complex can then bind 
gp130, which is expressed on a much wider variety of cell 
types. The presence of soluble IL-6R allows cell activation 
through gp130, a process known as trans-signaling, in tissues 
that do not constitutively express IL-6R (Rose-John 2003). 
This may help explain the diverse activities mediated by IL-6 
in systemic inﬂ  ammatory diseases such as RA.
Tocilizumab, previously known as myeloma receptor 
antibody (MRA), is a humanized, IgG1 IL-6 receptor mono-
clonal antibody that binds with high afﬁ  nity to the 80 kDa 
component of IL-6R. This binding subsequently inhibits 
dimerization of the IL-6/IL-6R complex with membrane-
bound gp130, preventing signaling.
The pharmacokinetics of tocilizumab were ﬁ  rst estab-
lished in a small, open-label study (Nishimoto et al 2003). 
Fifteen patients with active RA who had previously failed 
at least one DMARD or immunosuppressant received tocili-
zumab intravenously at doses of 2, 4, or 8 mg/kg biweekly 
for 6 weeks. The half-life of tocilizumab increased in a dose-
dependent manner, as well as with repeated dosing. After the 
third dose of 8 mg/kg, half-life reached a maximum of ~240 
hours. Serum tocilizumab concentrations were detectable 
during the entire study period in 4 of 5 patients in the 2 mg/kg 
group, 3 of 5 patients in the 4 mg/kg group, and all patients 
in the 8 mg/kg group, and decreased in a nonlinear manner. 
Those patients with detectable blood levels of tocilizumab 
maintained marked improvement in serum acute phase reac-
tants such as CRP and amyloid A.
Clinical trials
After its promising success in early open label studies, the 
efﬁ  cacy of tocilizumab in the treatment of RA was afﬁ  rmed 
in larger double-blind, placebo-controlled randomized 
trials (DBPCRT) (Table 1) (Yoshizaki et al 1998; Nishi-
moto et al 2003). A dose escalation study by Choy et al 
(2002) randomized 45 patients with active RA to receive a 
single intravenous (IV) dose of tocilizumab 0.1, 1.0, 5.0, or 
10.0 mg/kg or placebo. All patients had to have previously 
failed therapy with at least one DMARD. Improvement in 
disease activity was evaluated using the American College 
of Rheumatology (ACR) response criteria. At week 2, 55% of Therapeutics and Clinical Risk Management 2008:4(4) 769
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patients receiving 5 mg/kg of tocilizumab met the primary 
efﬁ  cacy endpoint (ACR20) compared with 0% in the placebo 
cohort. Efﬁ  cacy was maintained through week 8. However, 
no signiﬁ  cant difference could be observed between the other 
tocilizumab groups and placebo until week 6. Nonetheless, 
mean disease activity (assessed with the Disease Activity 
Score using a 28 joint count; DAS28) in the 5 mg/kg and 
10 mg/kg tocilizumab groups was statistically signiﬁ  cantly 
lower at day 14 than those in the 0.1 mg/kg and 1 mg/kg 
tocilizumab and placebo cohorts. Inﬂ  ammatory markers 
including the erythrocyte sedimentation rate (ESR) and CRP 
also decreased signiﬁ  cantly in the 5 mg/kg and 10 mg/kg 
tocilizumab groups and normalized after only 2 weeks of 
treatment.
A second multi-center DBPCRCT evaluated the efﬁ  cacy 
and safety of tocilizumab in 164 RA patients who had been 
refractory to multiple DMARDs (Nishimoto et al 2004). 
Patients received tocilizumab at doses of 4 mg/kg or 8 mg/kg 
IV or placebo every 4 weeks over a 3-month period. The 
primary endpoint was achievement of an ACR20 response at 
week 12 using the last observation carried forward (LOCF) 
method. Secondary endpoints consisted of improvement in 
the DAS28, frequency of ACR50 and ACR70 responses, 
improvement of variables in the ACR core set, and 
overall improvement in the ACR criteria. Tocilizumab signif-
icantly improved all measures of disease activity in the ACR 
core set in a dose-dependent manner, with response obvious 
at week 4 and escalating through week 12. At 3 months, 
78%, 57%, and 11% in the 8 mg/kg, 4 mg/kg, and placebo 
groups, respectively, achieved an ACR20. A statistically 
signiﬁ  cantly higher percentage of patients in the 8 mg/kg 
group (40%) attained an ACR50 response compared with the 
placebo group (1.9%). Furthermore, complete normalization 
of CRP was observed in 76% and 26% of patients in the 
8 mg/kg and 4 mg/kg groups versus only 1.9% of the placebo 
group. Of note, 5-year data from patients originally in this 
study that elected to continue tocilizumab in an open-label 
extension were recently reported (Nishimoto et al 2007a). 
Of the original 164 patients, 144 opted to continue treatment 
with tocilizumab at 8 mg/kg every 4 weeks. Importantly, 89 
of these patients had received tocilizumab for 5 years. At 
the 5-year assessment, 84% of patients met ACR20 criteria. 
Sustained improvement was also noted in the mean DAS28 
and Health Assessment Questionnaire (HAQ) scores, 
conﬁ  rming the persistent clinical utility of tocilizumab in 
long-term treatment.
The European Chugai Humanized Anti-Human Recom-
binant Interleukin-6 Monoclonal Antibody (CHARISMA) 
trial was the ﬁ  rst study to examine the effects of tocilizumab 
in conjunction with concomitant MTX (Maini et al 2006). 
Three hundred and ﬁ  fty-nine patients with moderately severe 
RA who were refractory to MTX therapy were randomized 
to 1 of 7 treatment arms; tocilizumab 2 mg/kg, 4 mg/kg, or 
8 mg/kg as monotherapy, the same doses in combination 
with MTX, or MTX plus placebo. Patients had failed an 
average of 5 DMARDs and almost 14% had received a TNF 
inhibitor prior to enrollment. The primary outcome measure 
at week 16 was a 20% improvement in ACR criteria, with 
mean change in DAS28 observed as the secondary end-
point. In the combination groups, an ACR20 response was 
achieved by a statistically signiﬁ  cantly greater number of 
patients compared with MTX plus placebo. However, this 
could not be demonstrated in the group receiving 2 mg/kg 
of tocilizumab as monotherapy. Additionally, those patients 
receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination 
with MTX also achieved an ACR50 and ACR70 response 
that was signiﬁ  cantly increased in comparison with MTX 
alone. These results indicate that tocilizumab is effective 
as monotherapy at the 4 mg/kg and 8 mg/kg dose, but also 
appears to have a synergistic effect in combination with 
methotrexate. Signiﬁ  cant changes in DAS28 scores were 
observed in a dose-dependent manner beginning at week 
4 (maximum reduction in the 8 mg/kg groups), and were 
maintained throughout the treatment period in all tocilizumab 
groups except patients administered 2 mg/kg of tocilizumab 
as monotherapy. Of patients in the 8 mg/kg combination 
group, 34% achieved remission as deﬁ  ned by a DAS28 
score 2.6, compared with only 8% of patients receiving 
MTX plus placebo (Prevoo et al 1996). Lastly, both ESR and 
CRP decreased markedly over time in all patients receiving 
tocilizumab except those assigned to 2 mg/kg monotherapy 
(ESR and CRP) and 4 mg/kg monotherapy (CRP only). 
Methotrexate plus placebo had very little effects on these 
parameters.
In the larger, more recent OPTION trial (Tocilizumab 
Pivotal Trial in Methotrexate Inadequate Responders), 632 
RA patients with moderate to severe disease were randomly 
assigned to receive IV tocilizumab 4 mg/kg or 8 mg/kg or 
placebo every 4 weeks (Smolen et al 2008). Enrolled patients 
had average disease duration of 7.5 years, a DAS28 score 
of 6.8, swollen joint count (SJC) 20, and tender joint count 
(TJC) 32. Less than 10% of patients had received prior anti-
TNF treatment. All three groups were continued on their pre-
study dose of methotrexate (~15 mg/week) throughout the 
24-week treatment period. The primary endpoint, an ACR20 
response, was observed in a signiﬁ  cantly higher proportion Therapeutics and Clinical Risk Management 2008:4(4) 771
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of patients receiving tocilizumab 4 mg/kg or 8 mg/kg (48% 
and 59%) versus methotrexate alone (26%). Additionally, 
more patients in the 8 mg/kg tocilizumab group achieved 
an ACR50 or ACR70 response compared with placebo. 
CRP and ESR in this group also decreased signiﬁ  cantly by 
week 2, and remained at normal levels throughout the study 
duration. Signiﬁ  cant reduction in the DAS28 score was 
recorded as early as 2 weeks at both doses of tocilizumab, 
and continued to improve through 6 months of treatment. 
More patients allocated to tocilizumab therapy also achieved 
DAS28 remission (~25%) than those receiving DMARDs 
alone (1%). Finally, a marked number of patients receiving 
tocilizumab also demonstrated good/moderate EULAR 
(European United League Against Rheumatism) response 
at 24 weeks (79.5% 8 mg/kg; 61.9% 4 mg/kg) compared 
with placebo (34.8%).
Investigation of tocilizumab in combination with a 
variety of DMARDs has also been recently reported. In 
the phase III, international TOWARD (Tocilizumab in 
Combination with Traditional DMARDs) trial, 1216 patients 
with moderate to severe RA who were inadequate responders 
to conventional DMARDs (MTX, sulfasalazine, leﬂ  unomide, 
chloroquine/hydroxychloroquine, azathioprine, or parenteral 
gold) were continued on their current therapy in addition to 
tocilizumab 8 mg/kg or placebo intravenously every 4 weeks 
for 24 weeks (Genovese et al 2007). Patients had an average 
disease duration of 9.8 years, DAS28 score of 6.6, TJC of 29, 
SJC 0f 19, HAQ score of 1.5, and a CRP of 2.6 mg/dL. At 
the primary evaluation point, patients receiving tocilizumab 
exhibited significantly higher ACR20/50/70 responses 
compared with placebo. ACR20 responses were seen in the 
tocilizumab group as early as week 2 as well as improvements 
in CRP and hemoglobin. Signiﬁ  cant changes in the mean 
DAS28, HAQ score, and ESR were also documented in 
the tocilizumab group when compared to DMARDs alone. 
This trial was important in demonstrating the superior 
efﬁ  cacy of tocilizumab in patients who are unable to tolerate 
methotrexate.
In addition to its clinical beneﬁ  ts, the ability of tocili-
zumab to alter the progression of joint damage in RA was 
examined in a prospective phase III study called SAMURAI 
(Study of Active Controlled Monotherapy Used for Rheuma-
toid Arthritis, an IL-6 inhibitor) (22). In this trial, 306 patients 
with RA of 5 years duration were randomized to receive 
either tocilizumab 8 mg/kg IV as monotherapy every 4 weeks 
or traditional DMARDs for 52 weeks. All patients had severe, 
active disease, with an average swollen and tender joint count 
12 and 14, ESR 70, CRP of 4.8 mg/dL, and a mean DAS28 
score of 6.5. The average number of DMARDs failed was 2 
with average disease duration of 2.3 years. Radiographs of 
the hands and feet were performed at baseline, 28, and 52 
weeks. Radiographic scoring was conﬁ  rmed by 2 independent 
readers blinded to both treatment group and chronological 
order using the van der Heijde’s modiﬁ  ed Sharp method. The 
mean total Sharp score (TSS) at baseline was 29.4, with an 
estimated yearly progression rate of 13.3 Sharp units. Sixty 
seven percent of patients received MTX as monotherapy or 
in combination with other DMARDs. As in other studies, 
treatment with tocilizumab monotherapy proved to be 
clinically superior to conventional DMARD therapy. At 
week 52, patients allocated to treatment with tocilizumab 
achieved an ACR20, ACR50, and ACR70 response of 
78%, 64%, and 44% in contrast to 34%, 13%, and 6% in the 
DMARD group, respectively. Clinical remission (DAS28  
2.6) was achieved in 59% of patients receiving tocilizumab 
and only 3% of patients receiving DMARDs (Prevoo et al 
1996). Substantial improvements in radiographic progression 
were also documented. The mean change in TSS at week 28 
was statistically signiﬁ  cantly less in the tocilizumab group 
compared to patients treated with traditional DMARDs 
and exhibited constant improvement until week 52. These 
changes correlated with a higher ACR response in both the 
tocilizumab and DMARD cohorts. Furthermore, erosion and 
joint space narrowing scores also showed signiﬁ  cantly less 
change in the tocilizumab group than in the DMARD group. 
These results indicate that tocilizumab is not only effective 
in managing the signs and symptoms of RA, but can help to 
sustain structural integrity of the joints.
Safety and tolerability
Safety remains an important concern for both physicians 
and patients when investigating any new therapy. To 
date, controlled trials and long-term follow-up of patients 
provide preliminary safety data on approximately 4000 RA 
patients who have received tocilizumab as monotherapy 
or in combination with other DMARDs, with more than 
5000 patient-years of follow-up. The most frequent adverse 
events recorded to date are discussed below. In the future, 
post-marketing surveillance and pharmacovigilance may 
help to elucidate additional data relevant to adverse events 
and their potential clinical impact.
Infections have been the most frequently reported adverse 
event linked to tocilizumab therapy in RA. The most com-
mon documented infections include nasopharyngitis and 
upper respiratory tract infection of mild to moderate severity. 
Serious infections, that is those requiring antibiotics and/or Therapeutics and Clinical Risk Management 2008:4(4) 772
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hospitalization, have been comprised of pneumonia, cellulitis, 
gastroenteritis, herpes zoster, herpes simplex, perianal abscess, 
osteomyelitis, infective arthritis, and sepsis (Maini et al 2006; 
Nishimoto et al 2007b). One patient in a trial died from 
disseminated Epstein-Barr virus (EBV) infection and subse-
quent hemophagocytic syndrome (Nishimoto et al 2004). In 
general, most studies show a small dose-dependent increase 
in the rate of serious infection associated with tocilizumab 
therapy compared with placebo. Larger studies with a more 
extensive period of exposure to study drug will be helpful to 
more accurately assess the risk of serious infection associated 
with tocilizumab treatment.
Increases in serum total cholesterol, LDL (low-density 
lipoprotein) and HDL (high- density lipoprotein) cholesterol, 
and triglycerides have been reported in many tocilizumab 
trials. In an earlier study, total cholesterol values in 44% 
of patients treated with tocilizumab increased in a dose-
dependent manner (Nishimoto et al 2004). Comparable 
elevations were noted in serum HDL and triglyceride levels. 
More recently, mean plasma concentrations of total, HDL, 
and LDL cholesterol were noted to be increased in patients 
receiving tocilizumab within the ﬁ  rst 6 weeks of treatment 
(Smolen et al 2008). These levels remained elevated through 
week 24, requiring 7 patients to begin lipid-lowering therapy 
according to protocol guidelines. Notably, there was no 
increase in cardiovascular events in this patient group com-
pared with placebo. Moderate, but reversible changes in 
non-fasting total cholesterol, HDL, and triglycerides were 
also documented during the CHARISMA trial in patients 
treated with tocilizumab (Maini et al 2006). Levels steadied 
after initial treatment and did not continue to increase with 
subsequent dosing. Importantly, the mean atherogenic index 
remained largely unchanged. Increases in cholesterol have 
also been reported with TNF inhibitors and may be related 
to the degree of inﬂ  ammatory suppression (Seriolo et al 
2006). Improvement therefore in overall disease activity may 
outweigh known risks of high serum cholesterol (ie, cardio-
vascular disease). This, however, remains to be elucidated 
in longer-term studies.
Tocilizumab treatment has also been associated with 
moderate increases in serum transaminases. In the CHARISMA 
trial, the mean AST (alanine aminotransferase) and ALT 
(aspartate aminotransferase) in all 127 patients who received 
tocilizumab exhibited elevations above normal levels (Maini 
et al 2006). This increase was accentuated in patients receiving 
concurrent MTX (2% of patients in the combination group 
had elevations 3-fold the upper limit of normal (ULN)). 
Five patients had to be withdrawn from the study due to ALT 
levels 100 IU/L. However, in the remaining patients, mean 
values returned to near-baseline within 8 weeks of the ﬁ  nal 
infusion. A gradual rise in bilirubin levels was also recorded, 
but appeared to have no correlation with elevations in ALT. 
Patients receiving MTX plus placebo demonstrated no increase 
in serum bilirubin. Raised levels of transaminases were also 
recorded in the OPTION trial (Smolen et al 2008). Of the 
patients receiving tocilizumab, 6% in the 4 mg/kg group and 
10% in the 8 mg/kg group had increases in ALT concentrations 
of more than 3 × /ULN compared with 4% of placebo patients. 
Eleven patients exhibited concentrations of 5 × /ULN. None 
of these patients demonstrated a concurrent increase in total 
bilirubin or alkaline phosphatase. These increases declined 
or normalized spontaneously or after disruption of treatment 
in the majority of patients, with no recurrent increase in ALT 
after the resumption of therapy. In a larger RA cohort, only 
1% of patients receiving tocilizumab in the TOWARD study 
had a transient ALT elevation 3 × ULN, with only 1 patient 
withdrawing (Genovese et al 2007). It is again important to 
note that these patients were also treated with concomitant 
DMARDs. No comments were made regarding elevations 
in serum bilirubin. To date, no cases of hepatitis or serious 
gastrointestinal (GI) events related to these ﬂ  uctuations in 
liver enzymes have been reported.
Reductions in the mean neutrophil count have also 
been observed with tocilizumab therapy. The initial study 
by Nishimoto observed decreases in white blood cell 
counts in 16% of patients allocated to tocilizumab (grade 
3 in 1 patient, grade 2 in 5 patients, and grade 1 in the 
remaining patients according to World Health Organization 
guidelines) (Nishimoto et al 2004). The decreases were 
transient and recovered without treatment within a few 
weeks. Only 1 patient withdrew from the study. Dose-
dependent decreases in the neutrophil count were also 
reported in the CHARISMA trial, again with normalization 
after the treatment period ended (Maini et al 2006). Lastly, 
transient neutrophil decreases in the OPTION trial were 
seen more often in patients treated with tocilizumab than 
in those of placebo (37 patients in the 4 mg/kg group, 67 in 
the 8 mg/kg groups, and 4 in the placebo group) (Smolen 
et al 2008). It is noteworthy that only a few patients treated 
with tocilizumab have developed absolute neutropenia 
(500 cells/mL) and that these decreases do not appear to 
increase susceptibility to infection.
Infusion reactions related to tocilizumab therapy 
have been mild to moderate, with 2 cases of nonserious 
anaphylaxis and hypersensitivity reactions described in 
one study (Maini et al 2006). Transient increases in blood Therapeutics and Clinical Risk Management 2008:4(4) 773
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pressure, injection site erythema, headache, nausea, and 
pruritis have also been reported (Nishimoto et al 2007b). Less 
than 1% of patients among the controlled trials discontinued 
therapy due to these effects.
The occurrence of malignancy in patients treated with 
tocilizumab has been reported in a single study. In the 
SAMURAI trial, 2 patients were diagnosed with breast cancer 
and a third with colon cancer (Nishimoto et al 2007b). All 
patients improved with directed therapy. No malignancies 
were reported in the DMARD group. Though other trials 
have not demonstrated an increased risk of malignancy with 
tocilizumab exposure, as with other biologics more long-term 
data are required.
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability/adherence
Patient-derived outcomes are essential in establishing the 
true efﬁ  cacy of any investigational drug. The inﬂ  uence of 
tocilizumab on health-related quality of life (HRQOL) and 
physical function in patients with RA has been analyzed in 
several large studies. In the OPTION trial, outcome measures 
including HAQ-Disability Index (HAQ-DI) and Functional 
Assessment of Chronic Illness Therapy-Fatigue scale 
(FACIT-Fatigue) were performed every 4 weeks. The Short 
Form 36 Health Survey (SF-36) was also assessed at base-
line, weeks 8, 16, and 24 (Smolen et al 2008). A signiﬁ  cant 
improvement from baseline HAQ-DI score was noted as early 
as week 4 in the tocilizumab groups, with 61% of patients in 
the 4 mg/kg cohort and 59% of patients in the 8 mg/kg cohort 
achieving an increase of 0.3 points or more at week 24 com-
pared with 47% of the placebo group. SF-36 physical com-
ponent score (PCS) and mental component score (MCS) also 
dramatically improved in patients allocated to tocilizumab 
therapy (p  0.0001). FACIT-Fatigue scores demonstrated 
considerable improvement in patients receiving tocilizumab 
compared to methotrexate alone (difference from placebo: 
4 mg/kg 3.3, 8 mg/kg 4.6). Importantly, the change from 
baseline scores in patients receiving tocilizumab exceeded 
accepted thresholds for minimal clinically important differ-
ence (MCID) for these measures. The results of this study 
concluded that tocilizumab therapy provided clinically 
meaningful improvement in HRQOL and physical function 
in patients with RA.
Treatment with tocilizumab during the TOWARD trial 
also resulted in early signiﬁ  cant and clinically relevant 
improvement in the HAQ, SF-36 score, and FACIT-Fatigue 
score at 24 weeks (Gomez-Reino et al 2007). Sixty percent 
of patients receiving tocilizumab versus 34% of patients 
taking conventional DMARDs showed marked changes 
in the mean HAQ scores at 6 months. Improvement in the 
FACIT-Fatigue score in the tocilizumab groups was observed 
as early as week 8, with changes in the MCID increasing 
to well above accepted standards by week 24. Statistically 
signiﬁ  cant improvements in the PCS and MCS and the 
individual domain scores of the SF-36 (physical function, 
physical role, bodily pain, general health, vitality, social 
functioning, emotional role, and mental health) were higher 
in the tocilizumab groups compared with placebo. Again, 
tocilizumab demonstrated signiﬁ  cant beneﬁ  t in patients 
with an inadequate response to DMARDs in all quality of 
life parameters.
Conclusions, place in therapy
Several published clinical trials have now established 
the efﬁ  cacy of tocilizumab, both as monotherapy and in 
combination with traditional DMARDs, in the treatment 
of moderate to severe RA (Ohsugi and Kishimmoto 2008). 
Signiﬁ  cant early improvements in accepted disease outcome 
measures including the ACR response criteria, HAQ, and 
DAS28, as well as enhancement of quality of life and overall 
function indicate substantial clinical beneﬁ  t over DMARD 
therapy alone.
Inhibition of radiographic progression and joint destruction 
in RA has also been suggested with tocilizumab monotherapy 
in open-label trials. Larger randomized controlled studies are 
needed to determine the effects of IL-6R blockade in erosive 
disease. These studies, as well as those to determine whether 
combination therapy with methotrexate will provide greater 
radiographic beneﬁ  t, are in progress.
Based on their extensive record of efﬁ  cacy and a safety 
accumulated for more than a decade, TNF inhibitors have 
become the biologic agent of choice for patients with RA, 
as well as for patients with other systemic inﬂ  ammatory 
diseases. However, despite the substantial efﬁ  cacy of these 
drugs, a subset of patients will exhibit a suboptimal response, 
either on account of incomplete or unsustained efﬁ  cacy or 
related to tolerability. Of note, increasing observational and 
anecdotal data suggest that switching among different TNF 
inhibitors may be a viable option. As newer biologic agents 
are introduced to the clinic, it is important to understand 
their efﬁ  cacy in patients who had previously been treated 
with TNF inhibitors. Such data have been published for 
biologic agents with other mechanisms of action, including 
the abatacept, an inhibitor of T-cell co-stimulation, and for 
rituximab, an anti-CD20 mAb that targets B cells. Similar Therapeutics and Clinical Risk Management 2008:4(4) 774
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data for IL-6 targeted therapies, in particular tocilizumab, 
are eagerly awaited.
Several doses of tocilizumab have been assessed in 
clinical trials and testing for optimum efﬁ  cacy at these and 
other levels continues. Evaluation of possible increased 
effectiveness with the addition of methotrexate or other 
DMARDs has also been previously estimated, but more 
studies to validate an observable difference are needed and 
are in progress. Combination therapy with other biologics 
may also be considered in prospective studies. However, 
because of current data surmised from published trials of 
combined biologic therapy, extreme caution will need to be 
implemented. Previous studies of a TNF inhibitor plus an 
IL-1 inhibitor or a T-cell costimulatory molecule antagonist 
showed no enhancement in efﬁ  cacy but deﬁ  nite increases in 
toxicity (Kavanaugh et al 2004).
Tocilizumab appears to have an acceptable safety proﬁ  le 
and is well-tolerated by most patients. Common laboratory 
abnormalities seen across clinical studies have included 
mild to moderate elevations in serum total cholesterol 
and its components (HDL, LDL, and triglycerides), AST 
and ALT, and decreases in absolute neutrophil count. To 
date, sequelae related to such events, such as increased car-
diovascular events, hepatic failure, or increased susceptibil-
ity to infection, have not been reported. At this time, the rate 
of serious infections appears comparable to that seen with 
other immunomodulatory biologic agents. Longer-term 
studies with increased patient exposure time are needed to 
more fully understand the risk of these events.
In future, it may be expected that we may see additional 
methods to target IL-6 as well as the application of IL-6 
inhibitors to systemic inﬂ  ammatory diseases besides RA. 
For example, blockade of IL-6 trans-signaling with a soluble 
gp130 protein (sgp130Fc) is now in preclinical trials and 
showing promise in a number of inﬂ  ammatory diseases 
(Rose-John et al 2007). In addition, tocilizumab has been 
approved in Japan for the treatment of RA, systemic onset 
juvenile idiopathic arthritis (JIA), and Castleman’s disease, a 
rare, lymphoproliferative disorder characterized by excessive 
IL-6 production (Nishimoto et al 2000; Yokota et al 2008). 
Children and adolescents afﬂ  icted with JIA are often resistant 
to treatment, including TNF inhibitors. Recent studies 
examining its efﬁ  cacy in Crohn’s disease and systemic lupus 
erythematosus (SLE) have also shown promise (Rose-John 
et al 2007; Ito 2005).
In summary, tocilizumab appears to be an emerg-
ing therapy for RA. Early studies have provided an 
acceptable profile but conclusions about the true safety 
of tocilizumab will need further evaluation through 
long-term studies.
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